PatenSee, a developer of fistula monitoring systems for dialysis patients, Fresenius Medical Care.
The companies will conduct a multicenter pilot trial of PatenSee’s contactless monitoring system within Fresenius Medical Care’s dialysis clinic in Israel.
This system is aimed at early detection of vascular access stenosis in hemodialysis patients.
It uses artificial intelligence (AI), machine learning, and multimodal imaging techniques to alert caregivers to the risk of access stenosis at an early stage.
Pilot trials are expected to begin in the first quarter of 2024.
PatenSee Chairman Shai Policker said: “Our goal with PatenSee is to improve the quality of patient monitoring and reduce complications while reducing the burden on clinical staff.
Access the most comprehensive company profiles on the market with GlobalData. Save research time. Increase competitiveness.
Company Profile – Free Sample
You will receive a download email shortly
We are confident in the unique quality of our company profile. However, we want you to make the decision that is most beneficial for your business, so we are offering free samples that you can download by submitting the form below.
by global data
“We are pleased to begin this new phase of implementing PatenSee’s contactless monitoring technology and are even more pleased to conduct this study in collaboration with Fresenius Medical Care, which has extensive experience and clinical expertise. think.”
PatenSee’s strategic plans include expanding this trial to other clinics in the United States.
The goal is to collect enough data to seek U.S. Food and Drug Administration (FDA) approval for the non-contact monitoring system.
“Timely monitoring and analysis of fistula status in hemodialysis patients is a major unmet clinical need,” said Adi Shaked, venture innovation manager at Fresenius Medical Care Israel. “PatenSee’s contactless and rapid monitoring could have a significant impact on dialysis patients.”
Last year, Fresenius Secure a 510(k) clearance from FDA for VersiHD and GuideMe software are designed to enhance patient training time and ease the transition of patients home.
The new self-guided interface is used in the company’s VersiHD chronic home hemodialysis system.
The software provides graphical walk-through guidance, improving ease of use for both nurses and patients.
